Phospho-EGFRTyr992 is synergistically repressed by co-inhibition of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K), which attenuates resistance to erlotinib in head and neck cancer cells

BACKGROUND: Erlotinib is a commonly used epidermal growth factor receptor (EGFR)-targeted therapeutic choice for head and neck squamous cell carcinoma; however, its efficacy is largely compromised by cancer cell resistance. Understanding and targeting the erlotinib adaptive mechanisms of squamous ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xuejun, Gao, Wen, Yin, Gaofei, Guo, Wei, Huang, Junwei, Huang, Zhigang, Zhang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506790/
https://www.ncbi.nlm.nih.gov/pubmed/34734007
http://dx.doi.org/10.21037/atm-21-4335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506790/
https://www.ncbi.nlm.nih.gov/pubmed/34734007
http://dx.doi.org/10.21037/atm-21-4335

Ejemplares similares